Overexpression of fibroblast growth factor receptor 3 (FGFR3) has been shown to drive oncogenesis in a subset of patients with multiple myeloma. However, epithelial cancers — such as bladder ...

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

Around 20 percent of people with advanced or metastatic bladder cancer have FGFR3 alterations, which can drive the growth of cancer cells. “Patients living with this advanced stage of bladder ...

Johnson & Johnson's Balversa has become the first drug approved in the EU to treat adults with advanced urothelial carcinoma (mUC) with FGFR3 genetic ... common form of bladder cancer.

NDAQ:TYRA) Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) ...

FGFR3 is the most frequently altered gene in ... "For the last thirty years, I have dedicated my career to helping patients with bladder cancer as a urologic oncologist, a principal investigator ...

intermediate risk non-muscle invasive bladder cancer (IR NMIBC). The investigational drug TYRA-300 is a selective inhibitor designed specifically to target FGFR3 mutations, which are commonly ...

FGFR3 is the most frequently altered gene in ... medically and surgically, with bladder, prostate, and kidney cancers. He was a principal investigator for multiple clinical trials and has ...

Tyra Biosciences, Inc. (NASDAQ: TYRA) shares decreased in price Friday. The Carlsbad, Calif.-based Tyra, a clinical-stage biotechnology company focused on developing next-generation precision ...